首页|探讨托伐普坦治疗老年慢性心力衰竭合并低钠血症的疗效与安全性

探讨托伐普坦治疗老年慢性心力衰竭合并低钠血症的疗效与安全性

扫码查看
目的 探讨托伐普坦治疗老年慢性心力衰竭合并低钠血症的疗效与安全性。方法 选取2022年4月—2023年4月本院收治的96例老年慢性心力衰竭合并低钠血症患者为研究对象,入院后以电脑随机法分为对照组(n=48)、观察组(n=48)两组,分别给予高渗盐水联合呋塞米治疗和托伐普坦治疗,并对比临床各项指标、临床治疗效果及不良反应发生率。结果 观察组较对照组,临床各项指标均明显得到改善、临床治疗效果明显、不良反应发生率低,上述指标对比均有统计学意义(P<0。05)。结论 托伐普坦治疗老年慢性心力衰竭合并低钠血症,其临床效果显著,不仅可以改善患者的临床各项指标,还提高了临床用药的安全性。可在临床上推广应用。
Curative Effect and Safety Exploriation of Tovastatin in Treatment of Elderly Chronic Heart Failure with Hyponatremia
Objective To explore effect and safety of tocilizuman in treatment of elderly chronic heart failure with hyponatremia.Methods The paper chose 96 elderly patients with chronic heart failure complicated with hyponatremia admitted to our hospital from April 2022 to April 2023 as study subjects,and divided them into control group(n=48)and observation group(n=48)randomly with computer randomization,treated with hypertonic saline combined with furosemide and tofaciptan respectively.Clinical indicators,curative effect,and incidence of adverse reactions were compared.Results Clinical indicators in observation group were significantly better than control group,with significant clinical treatment effect.Incidence of adverse reactions was lower,comparison of indicators was statistically significant(P<0.05).Conclusion Tovastatin can achieve significant clinical effect for elderly patients with chronic heart failure complicated with hyponatremia,can improve various clinical indicators,enhance safety of clinical medication,which can be promoted and applied in clinical practice.

TovaptanElderly chronic heart failureHyponatremiaSafety

周锦程

展开 >

株洲清水塘医院,湖南 株洲 412000

托伐普坦 老年慢性心力衰竭 低钠血症 安全性

2024

智慧健康

智慧健康

ISSN:
年,卷(期):2024.10(6)
  • 11